(secondQuint)ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse.

 OBJECTIVES: - Determine the activity of ZD 1839 in patients with glioblastoma multiforme in first relapse.

 - Determine the pharmacokinetics and toxicity of this drug in these patients.

 - Assess the relationship between epidermal growth factor receptor status in these patients and activity of this drug.

 OUTLINE: Patients receive oral ZD 1839 once daily.

 Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

 Patients are followed for at least 6 months.

 PROJECTED ACCRUAL: A total of 53 patients will be accrued for this study within 12-18 months.

.

 ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse@highlight

RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of glioblastoma multiforme.

 PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have glioblastoma multiforme in first relapse.

